P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000971368.08106.5c |
| _version_ | 1797280001016463360 |
|---|---|
| author | Wojciech Jurczak Herve Ghesquieres Yasmin Karimi Chan Cheah Michael Roost Clausen David Cunningham Young Rok Do David Lewis Robin Gasiorowski Tae Min Kim Marjolein Van Der Poel Michelle Limei Poon Tatyana Feldman Kim Linton Anna Sureda Martin Hutchings Salim Kanoun Laetitia Vercellino Mariana Cota Stirner Stephanie Mcgoldrick Yan Liu Mariana Sacchi Pieternella Lugtenburg Catherine Thieblemont |
| author_facet | Wojciech Jurczak Herve Ghesquieres Yasmin Karimi Chan Cheah Michael Roost Clausen David Cunningham Young Rok Do David Lewis Robin Gasiorowski Tae Min Kim Marjolein Van Der Poel Michelle Limei Poon Tatyana Feldman Kim Linton Anna Sureda Martin Hutchings Salim Kanoun Laetitia Vercellino Mariana Cota Stirner Stephanie Mcgoldrick Yan Liu Mariana Sacchi Pieternella Lugtenburg Catherine Thieblemont |
| author_sort | Wojciech Jurczak |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:33:56Z |
| format | Article |
| id | doaj.art-e0f9fede8f014c7495ab4f4759ea8757 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:33:56Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-e0f9fede8f014c7495ab4f4759ea87572024-03-03T10:04:28ZengWileyHemaSphere2572-92412023-08-017e081065c10.1097/01.HS9.0000971368.08106.5c202308003-01016P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMAWojciech Jurczak0Herve Ghesquieres1Yasmin Karimi2Chan Cheah3Michael Roost Clausen4David Cunningham5Young Rok Do6David Lewis7Robin Gasiorowski8Tae Min Kim9Marjolein Van Der Poel10Michelle Limei Poon11Tatyana Feldman12Kim Linton13Anna Sureda14Martin Hutchings15Salim Kanoun16Laetitia Vercellino17Mariana Cota Stirner18Stephanie Mcgoldrick19Yan Liu20Mariana Sacchi21Pieternella Lugtenburg22Catherine Thieblemont231 MSC National Research Institute of Oncology, Kraków, Poland,2 Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France,3 University of Michigan Comprehensive Cancer Center,, Ann Arbor, United States,4 Sir Charles Gairdner Hospital, Nedlands, Australia,5 Vejle Hospital, Vejle, Denmark,6 The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom,7 Keimyung University Dongsan Medical Center, Daegu, Korea, Rep. of South,8 University Hospitals Plymouth NHS Trust, Derriford Hospital, Plymouth, United Kingdom,9 Concord Hospital, University of Sydney, Sydney, Australia,10 Seoul National University Hospital, Seoul, Korea, Rep. of South,11 On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Maastricht, Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands,12 National University Hospital, Singapore, Singapore,13 Hackensack Meridian Health Hackensack University Medical Center, Hackensack, United States,14 The Christie NHS Foundation Trust and Manchester Cancer Research Centre, Manchester, United Kingdom,15 Institut Català d’Oncologia, Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain,16 Rigshospitalet, Copenhagen University Hospital,, Copenhagen, Denmark,17 Cancer Research Center of Toulouse, Toulouse, France,18 Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Médecine Nucléaire, Université de Paris, Paris, France,19 AbbVie, North Chicago, United States,20 Genmab, Princeton, United States,20 Genmab, Princeton, United States,20 Genmab, Princeton, United States,21 On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, The Netherlands,22 Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Paris, Francehttp://journals.lww.com/10.1097/01.HS9.0000971368.08106.5c |
| spellingShingle | Wojciech Jurczak Herve Ghesquieres Yasmin Karimi Chan Cheah Michael Roost Clausen David Cunningham Young Rok Do David Lewis Robin Gasiorowski Tae Min Kim Marjolein Van Der Poel Michelle Limei Poon Tatyana Feldman Kim Linton Anna Sureda Martin Hutchings Salim Kanoun Laetitia Vercellino Mariana Cota Stirner Stephanie Mcgoldrick Yan Liu Mariana Sacchi Pieternella Lugtenburg Catherine Thieblemont P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA HemaSphere |
| title | P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA |
| title_full | P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA |
| title_fullStr | P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA |
| title_full_unstemmed | P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA |
| title_short | P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA |
| title_sort | p1118 longer follow up from the pivotal epcore nhl 1 trial reaffirms subcutaneous epcoritamab induces deep durable complete remissions in patients with relapsed refractory large b cell lymphoma |
| url | http://journals.lww.com/10.1097/01.HS9.0000971368.08106.5c |
| work_keys_str_mv | AT wojciechjurczak p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT herveghesquieres p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT yasminkarimi p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT chancheah p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT michaelroostclausen p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT davidcunningham p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT youngrokdo p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT davidlewis p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT robingasiorowski p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT taeminkim p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT marjoleinvanderpoel p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT michellelimeipoon p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT tatyanafeldman p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT kimlinton p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT annasureda p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT martinhutchings p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT salimkanoun p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT laetitiavercellino p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT marianacotastirner p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT stephaniemcgoldrick p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT yanliu p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT marianasacchi p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT pieternellalugtenburg p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma AT catherinethieblemont p1118longerfollowupfromthepivotalepcorenhl1trialreaffirmssubcutaneousepcoritamabinducesdeepdurablecompleteremissionsinpatientswithrelapsedrefractorylargebcelllymphoma |